Equity Offerings
-
-
-
-
-
-
-
Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
-
-
-
-
-
-
-
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
-
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
12,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

